http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004022095-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f779987fc6c26b46c48edc29dd73b020
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58f57e36dac603e10373a7e4866e1596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcc664f72915247f2a2cba7b93ef3c8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_46e8c10c6fe79854db8512f9e730f069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faa75547136d2ba68ac9001ab13e5d84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0b7aa52cc944f2eaab4fac877655b03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d54c6b08608c592b6bae2f5dda72dee
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08
filingDate 2003-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3041d45bd8c1c8855c991cc37c0cf1f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb4e7b21618ae3f3e8ec703294504850
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01bbf06d7d2ea026dba7c3b4d60c7a27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e89148471122cc50c196d0fa462f93af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbd8b4d3d46dec26fdf8c4010c738855
publicationDate 2004-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2004022095-A1
titleOfInvention Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
abstract The invention relates to a pharmaceutical composition for bone therapy comprising a therapeutically effective amount of at least one agonist of a vascular endothelial factor (VEGF) or a fibroblast growth factor (FGF) receptor.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8835385-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10570205-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9493577-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1752163-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9493530-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1752163-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8187601-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11072640-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8795985-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11505611-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8372952-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9284378-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9279013-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112094351-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8324160-B2
priorityDate 2002-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9641523-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0064261-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0104160-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0236732-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9723510-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91670
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395300

Total number of triples: 50.